SK Biopharmaceuticals Co., Ltd. Stock

Equities

A326030

KR7326030004

Pharmaceuticals

End-of-day quote Korea S.E. 18:00:00 2024-06-18 EDT 5-day change 1st Jan Change
77,400 KRW +0.65% Intraday chart for SK Biopharmaceuticals Co., Ltd. -3.01% -22.91%

Financials

Sales 2024 * 492B 356M 488M Sales 2025 * 643B 465M 638M Capitalization 6,061B 4.38B 6.01B
Net income 2024 * 36B 26.03M 35.68M Net income 2025 * 118B 85.31M 117M EV / Sales 2024 * 12.1 x
Net cash position 2024 * 121B 87.31M 120M Net cash position 2025 * 218B 157M 216M EV / Sales 2025 * 9.08 x
P/E ratio 2024 *
160 x
P/E ratio 2025 *
48.2 x
Employees 252
Yield 2024 *
-
Yield 2025 *
-
Free-Float 35.75%
More Fundamentals * Assessed data
Dynamic Chart
SK Biopharmaceuticals Turns to Profit in Q1 as Sales Jump 88% MT
SK Biopharmaceuticals Swings to Profit in Q4 MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd.. CI
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2% MT
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division MT
SK Biopharmaceuticals Continues to Report Losses in Q2 MT
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation CI
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029 MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million. CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SK Biopharmaceuticals Narrows Loss in Q1 MT
SK Biopharmaceuticals Swings to Loss in Q4 MT
More news
1 day+0.65%
1 week-3.01%
Current month-9.37%
1 month-13.62%
3 months-17.13%
6 months-15.04%
Current year-22.91%
More quotes
1 week
76 500.00
Extreme 76500
79 900.00
1 month
76 500.00
Extreme 76500
88 700.00
Current year
76 500.00
Extreme 76500
104 800.00
1 year
72 700.00
Extreme 72700
104 800.00
3 years
50 900.00
Extreme 50900
137 500.00
5 years
50 900.00
Extreme 50900
269 500.00
10 years
50 900.00
Extreme 50900
269 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 22-12-31
Corporate Officer/Principal - 22-12-31
Corporate Officer/Principal - 17-03-15
Members of the board TitleAgeSince
Director/Board Member 60 17-03-15
Corporate Officer/Principal - 17-03-15
Director/Board Member - 19-08-26
More insiders
Date Price Change Volume
24-06-19 77,400 +0.65% 73,049
24-06-18 76,900 -1.41% 77,380
24-06-17 78,000 -0.38% 98,878
24-06-14 78,300 -1.51% 122,698
24-06-13 79,500 -0.38% 142,473

End-of-day quote Korea S.E., June 18, 2024

More quotes
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
77,400 KRW
Average target price
107,250 KRW
Spread / Average Target
+38.57%
Consensus
  1. Stock Market
  2. Equities
  3. A326030 Stock